Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Immune checkpoint protein (ICP), which is a central factor group of the immune system, has been reported to have a correlation between the degree of its expression and the prognosis of patients with malignant tumors, and many inhibitors have appeared as therapeutic targets. On the other hand, a soluble form of ICP in circulating blood induced systemic immunosuppression. In this study, we investigated the relationship between the soluble form of CD80 (sCD80) which is a ligand for the inhibitory system CTLA-4, in blood, and clinicopathological parameters in patients with soft tissue tumors. A total of 119 patients with primary soft tissue tumors were enrolled in this study. The sCD80 levels were measured by enzyme immunoassay. There were no significant differences in sCD80 levels between benign (34) and soft tissue sarcoma (STS) patients (85). In STS, the high-sCD80 group had significantly lower metastasis-free survival (MS) and lower overall survival (OS) than the low-sCD80 group at 5 years using the log-rank test (OS: high > 404 pg/mL, low ≤ 404 pg/mL, MS: high > 531 pg/ml, low ≤ 531 pg/ml). On multivariate Cox proportional hazard analysis, the high-sCD80 group had significant differences in 5MS and 5OS compared to the low-sCD80 group. In conclusion, sCD80 may negatively affect systemic immune circumstances, in STS, and may have potential as a therapeutic target. © 2022. The Author(s).

Citation

Yumi Matsuyama, Kunihiro Asanuma, Keisuke Yoshida, Tomohito Hagi, Takahiro Iino, Tomoki Nakamura, Akihiro Sudo. The role of soluble CD80 in patients with soft tissue tumors. Journal of orthopaedic surgery and research. 2022 Sep 05;17(1):404

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 36064421

View Full Text